JP2023518543A - Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用 - Google Patents

Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用 Download PDF

Info

Publication number
JP2023518543A
JP2023518543A JP2022556248A JP2022556248A JP2023518543A JP 2023518543 A JP2023518543 A JP 2023518543A JP 2022556248 A JP2022556248 A JP 2022556248A JP 2022556248 A JP2022556248 A JP 2022556248A JP 2023518543 A JP2023518543 A JP 2023518543A
Authority
JP
Japan
Prior art keywords
alkyl
compound
optionally substituted
halogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518543A5 (https=
Inventor
イー． フレミング ポール
ピー． ブライスデル トーマス
ラオ アッル センカラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of JP2023518543A publication Critical patent/JP2023518543A/ja
Publication of JP2023518543A5 publication Critical patent/JP2023518543A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022556248A 2020-03-20 2021-03-19 Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用 Pending JP2023518543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992616P 2020-03-20 2020-03-20
US62/992,616 2020-03-20
PCT/US2021/023228 WO2021188944A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and their use

Publications (2)

Publication Number Publication Date
JP2023518543A true JP2023518543A (ja) 2023-05-02
JP2023518543A5 JP2023518543A5 (https=) 2024-05-29

Family

ID=75478265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556248A Pending JP2023518543A (ja) 2020-03-20 2021-03-19 Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用

Country Status (6)

Country Link
US (1) US20230212138A1 (https=)
EP (1) EP4121424A1 (https=)
JP (1) JP2023518543A (https=)
CN (2) CN120004851A (https=)
AR (1) AR121626A1 (https=)
WO (1) WO2021188944A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
EP4447963A1 (en) * 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
CN118745146B (zh) * 2024-06-24 2025-09-23 上海坦泰生物科技有限公司 一种5-氟-2-肼基吡啶二盐酸盐的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255788A (ja) * 1984-05-23 1985-12-17 バイエル・アクチエンゲゼルシヤフト １‐ヘテロアリール‐４‐アリール‐ピラゾリン‐５‐オン
JPS61137878A (ja) * 1984-11-28 1986-06-25 バイエル・アクチエンゲゼルシヤフト 薬剤用１‐ヘテロアリール‐４‐アリール‐ピラゾリン‐５‐オン類
JP2010507602A (ja) * 2006-10-26 2010-03-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心血管および血液の疾患の処置用の置換ジヒドロピラゾロン類
JP2016501882A (ja) * 2012-12-06 2016-01-21 クオンティセル ファーマシューティカルズ，インク． ヒストンデメチラーゼ阻害剤
JP2016515582A (ja) * 2013-03-29 2016-05-30 武田薬品工業株式会社 ６−（５−ヒドロキシ−１ｈ−ピラゾール−１−イル）ニコチンアミド誘導体およびｐｈｄ阻害剤としてのそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050512A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102007044032A1 (de) * 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
WO2010005851A1 (en) * 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255788A (ja) * 1984-05-23 1985-12-17 バイエル・アクチエンゲゼルシヤフト １‐ヘテロアリール‐４‐アリール‐ピラゾリン‐５‐オン
JPS61137878A (ja) * 1984-11-28 1986-06-25 バイエル・アクチエンゲゼルシヤフト 薬剤用１‐ヘテロアリール‐４‐アリール‐ピラゾリン‐５‐オン類
JP2010507602A (ja) * 2006-10-26 2010-03-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心血管および血液の疾患の処置用の置換ジヒドロピラゾロン類
JP2016501882A (ja) * 2012-12-06 2016-01-21 クオンティセル ファーマシューティカルズ，インク． ヒストンデメチラーゼ阻害剤
JP2016515582A (ja) * 2013-03-29 2016-05-30 武田薬品工業株式会社 ６−（５−ヒドロキシ−１ｈ−ピラゾール−１−イル）ニコチンアミド誘導体およびｐｈｄ阻害剤としてのそれらの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"PUBCHEM CID 135129723", CREATE DATE: 2018年12月15日, JPN6025005432, ISSN: 0005525618 *
BECK, H. ET AL.: ""Discovery of Molidustat (BAY85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibi", CHEMMEDCHEM, vol. 13, no. 10, JPN6025005433, 2018, pages 988 - 1003, ISSN: 0005525617 *

Also Published As

Publication number Publication date
AR121626A1 (es) 2022-06-22
CN115605467B (zh) 2025-06-13
EP4121424A1 (en) 2023-01-25
CN115605467A (zh) 2023-01-13
TW202140444A (zh) 2021-11-01
CN120004851A (zh) 2025-05-16
US20230212138A1 (en) 2023-07-06
WO2021188944A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
JP2023518543A (ja) Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP2026021443A (ja) Ｐｈｄ阻害剤化合物、組成物、および使用
JP2023518262A (ja) Ｐｈｄ阻害剤化合物、組成物、及び使用
JP7832179B2 (ja) Ｐｈｄ阻害剤化合物、組成物、及び使用方法
CN111902404A (zh) 治疗化合物和组合物
TWI917364B (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
BR122025027329A2 (pt) Compostos, composição farmacêutica e uso
WO2025137158A1 (en) Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
BR122025027331A2 (pt) Compostos, composição farmacêutica e uso
JP2024546944A (ja) Ｒｘｆｐ１アゴニストとしてのナフタレンおよびキノリン類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260423